Isabella Tree

Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence

Retrieved on: 
Dienstag, Mai 28, 2024

11

Key Points: 
    • 11

      Reflection paper on use of real-world data in noninterventional studies to generate real-world evidence

      12

      Table of contents

      13

      1.

    • References ............................................................................................ 15

      10

      Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 2/16

      44

      1.

    • Introduction

      45

      This reflection paper discusses methodological aspects of non-interventional studies (NIS) using real-

      46

      world data (RWD) in order to generate real-world evidence (RWE) for regulatory purposes.

    • These include absence of randomisation, uncontrolled conditions, non-

      61

      standardised treatments and uncertainties regarding data quality and completeness.

    • The

      63

      increasing ability to capture electronic healthcare data and data from registries is now providing new

      64

      opportunities to use RWD and generate RWE that reflects clinical practice.

    • Scope

      89

      The scope of this reflection paper is the design, conduct and analysis of NIS using RWD to generate

      90

      RWE for regulatory purposes.

    • data collected specifically for the study in

      106

      question, or secondary use of existing data sources.

    • In both cases, attention should be paid to the

      107

      possible selection mechanisms in the data collection, for example the inclusion of specific patients or

      108

      the collection of specific clinical data.

    • Reference to studies with causal objectives in this document does not

      119

      imply an expectation that specific analytical methods will be used.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 4/16

      128

      The legal obligations and regulatory requirements applicable to NIS should be followed.

    • 138

      ?

      Regulation (EU) 2016/679 on the protection of natural persons with regard to the processing of

      139
      140

      personal data and on the free movement of such data.

    • The specific aim of the study forms the basis for the

      164

      selection of data source(s), study design, and analysis approach.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 5/16

      166

      4.2.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 6/16

      208

      ?

      Regional differences in clinical practice and healthcare systems management, e.g.

    • Misclassification can arise at many different

      296

      steps of data collection and extraction: diagnosis, coding, recording, data transformation, data

      297

      aggregation, summarisation, and analysis.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 12/16

      452

      6.4.

    • For these studies, the study protocol should describe:

      456

      ?

      The data elements used to link the data.

    • Heterogeneity

      530

      In multi-database studies, different estimates may be found even when the same protocol is applied

      531

      across all data sources (22).

    • (2023)
      Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 15/16

      569
      570

      15.

    • Draft guidance Real-World Data: Assessing Electronic Health Records and Medical Claims
      Data To Support Regulatory Decision-Making for Drug and Biological Products (2021)

      571
      572
      573

      16.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 16/16

Household inflation expectations: an overview of recent insights for monetary policy

Retrieved on: 
Dienstag, Mai 28, 2024
Diamond, Directorate, Investment, Section 3, Sum, Canadian International Council, Journal of Consumer Affairs, Q&A, Motivation, American Economic Journal, European Economic Review, NBER, Credit, Vol, Long Shadow, Thumb, Trust, Semantics, Optimism, Research, American Economic Review, Journal of Monetary Economics, Disinflation, Central bank, Paper, Statistics, University of Chicago, Doepke, Movement, Economic Inquiry, Consumer protection, Collection, Topa, Federal Reserve Bank, Journal, Isabella Tree, Clinical study design, Section 2, International Economic Review, Cross, UC, Consumer confidence index, Prevalence, University, Suite, Overweight, Quarterly Journal of Economics, Appendix, Diffusion, DNB, Knowledge, Economy, Hand, Journal of Economics, German reunification, Macmillan Inc., Blinder, News, Risk, Emotion, International finance, Monetary economics, Quarterly Journal, Elsevier, Figure, FOMC, ECB, Importance, International economics, Journal of Financial Economics, Pessimism, Shleifer, Housing, Deutsche Bundesbank, Communication, 2022–23 Feyenoord season, Journal of Economic Literature, R.E, Behavior, Expected shortfall, Journal of International Economics, Skill, Consumer, COVID-19, Economic methodology, Employment, Macmillan Publishers, Forecasting, Bank, Fed, Policy, Attention, HICP, Memory, Patzelt, Communism, Environment, Acceleration, Female, CPI, Political economy, Working paper, Code, E31, Bank of England, Woman, Small business, Male, European, The Journal of Finance, See, Growth, American Economic Association, Observation, Electricity, Thought, Noise, RCT, Supermarket, Food, Persistent, Section 5, General Public, Probability, Synthetic control method, Social capital, Transmission, IMF Economic Review, Annual Review of Economics, National academy, Shock, Financial economics, Literacy, SCE, Journal of Political Economy, Second, George Selgin, Lane, Parent, Television, Intuition, SPF, Econometric Society, Inflation, Federal Open Market Committee, Cambridge University Press, Transport, Manuscript, Section 4, Bias, Maurice Vellekoop, Social media, Mishkin, FIRE, European Economic Association, Erosion, Academic Press, University of California, Berkeley, Learning, Neutral, Lighting, De Nederlandsche Bank, Internet, Traction, European Commission, Face, Methodology, European Central Bank, Data collection, Literature, Rate, Politics, New Keynesian economics, Radio, Ball, Journal of Economic Psychology, ELB, African Americans, CES, Acquisition, Logic, Cryptocurrency

Key Points: 

    Saga Education and Success for All Selected as High-Impact Tutoring Partners for Michigan School Districts

    Retrieved on: 
    Dienstag, März 19, 2024

    In 2023, Saga Education and Success for All formed a partnership to support districts and state education agencies with tutoring in early literacy and middle/late grades math.

    Key Points: 
    • In 2023, Saga Education and Success for All formed a partnership to support districts and state education agencies with tutoring in early literacy and middle/late grades math.
    • "Saga Education is honored to be selected as an approved, high-impact tutoring technical assistance partner for Michigan school districts," said Alan Safran, CEO and co-founder of Saga Education.
    • Success for All offers Michigan school districts Success for All (SFA) Tutoring, a research-proven, web-based literacy tutoring for below-level students in grades 1-8.
    • Success for All looks forward to supporting Michigan school districts in accelerating their students' growth in essential literacy skills," said Julie Wible, Success for All CEO.

    Real-World Data on Human Milk-Based Fortification Reveals Limitations of Protocol Designs of Two RCTs

    Retrieved on: 
    Dienstag, Februar 6, 2024

    DUARTE, Calif., Feb. 6, 2024 /PRNewswire/ -- Optimizing nutrition for premature infants remains an important focus in neonatal care. More than 20 peer-reviewed studies of 5,000+ preterm infants demonstrated that, compared to bovine milk-based fortifiers (BMBF), Prolacta Bioscience's human milk-based fortifiers (HMBF) improve growth and development1-7 and provide clinically significant reductions in comorbidities.1,2,8-20 The health benefits from the use of HMBF have also shown significant annual cost savings for hospitals.8 More than 100,000 critically ill and preterm infants have received Prolacta's human milk-based nutritional products.21

    Key Points: 
    • While the RCTs were intended to provide a head-to-head comparison between fortifier products, the feeding protocols fundamentally differed.
    • HMBF recommendations for best outcomes regarding the day fortification should begin and the speed at which feeds are advanced were not followed in either study.
    • Given these known risks, randomizing extremely premature infants to day-one fortification with BMBF would unjustly endanger this vulnerable patient population.
    • Extensive real-world data affirm EHMD adoption enables critical health improvements for premature infants and major cost reductions for hospitals.

    Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance

    Retrieved on: 
    Dienstag, Januar 9, 2024

    IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.

    Key Points: 
    • IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.
    • Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be at least $132.0 million, up approximately 22% year-over-year.
    • Preliminary unaudited revenue for the full year 2023 is expected to be at least $493.5 million, up approximately 29% over the full year 2022.
    • Further detail will be provided when Inari reports its financial results for the fourth quarter and full year 2023.

    Large-Scale Real-World Study Demystifies UroLift™ System Durability and Reinforces Superior Patient Experience for Men With Enlarged Prostate Compared to Leading Surgical Treatments

    Retrieved on: 
    Dienstag, November 14, 2023

    However, comparing different randomized controlled trials (RCTs) for these outcomes can be limited and misleading due to varying methodologies.

    Key Points: 
    • However, comparing different randomized controlled trials (RCTs) for these outcomes can be limited and misleading due to varying methodologies.
    • This first-of-its-kind study overcomes these limitations and directly compares and analyzes outcomes in over 40,000 real-world BPH patients by applying a consistent definition of retreatment across the leading BPH treatments.
    • * The retreatment rate for UroLift™ PUL (11.6%) is comparable to published controlled trial rates, thereby underscoring and demystifying the durability of the UroLift™ System.
    • Under this definition, at one-year procedural complications were lowest following the UroLift™ System (15%) and highest following Rezūm™ WVTT (26%).

    Pusan National University Researchers Dive Deep Into the Safety of JAK Inhibitors for Atopic Dermatitis

    Retrieved on: 
    Freitag, Dezember 15, 2023

    In this context, Janus kinase (or JAK) inhibitors are small molecules that have emerged as a promising treatment option for managing AD.

    Key Points: 
    • In this context, Janus kinase (or JAK) inhibitors are small molecules that have emerged as a promising treatment option for managing AD.
    • However, the FDA has also issued a boxed warning for JAK inhibitors to include the risk of major adverse events.
    • Since then, many meta-analyses focusing on the safety of JAK inhibitors have been published, but these analyses are fraught with several limitations.
    • Title of original paper: The safety of systemic Janus kinase inhibitors in atopic dermatitis:

    Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

    Retrieved on: 
    Mittwoch, November 29, 2023

    OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

    Key Points: 
    • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
    • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
    • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
    • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

    Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

    Retrieved on: 
    Mittwoch, November 29, 2023

    OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

    Key Points: 
    • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
    • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
    • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
    • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

    Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23

    Retrieved on: 
    Dienstag, Oktober 31, 2023

    Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.

    Key Points: 
    • Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
    • Results from Abbott's LIFE-BTK randomized clinical trial (RCT) demonstrate that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.
    • In the LIFE-BTK trial, wound assessment was not a prespecified powered primary or secondary endpoint but rather a prespecified descriptive endpoint.
    • The trial offers the largest ischemic wound data set to date, collected systematically and adjudicated independently in a blinded fashion.